MTOR and hepatocellular carcinoma: In stark contrast, a significant survival benefit has been consistently observed in a specific clinical setting: for HCC patients undergoing liver transplantation, an immunosuppressive regimen based on mTOR inhibitors (sirolimus or everolimus) has been shown to improve both overall and recurrence-free survival 106.